Anzeige
Mehr »
Sonntag, 03.08.2025 - Börsentäglich über 12.000 News
Das Antimon-Erwachen: Warum dieser übersehene kanadische Explorer eine der hochgradigsten Entdeckungen Nordamerikas besitzen könnte
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3C53B | ISIN: US98422T1007 | Ticker-Symbol:
NASDAQ
01.08.25 | 21:59
0,650 US-Dollar
+0,18 % +0,001
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
XILIO THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
XILIO THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur XILIO THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrXilio Therapeutics, Inc.: Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)42WALTHAM, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies...
► Artikel lesen
02.07.Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)84WALTHAM, Mass., July 02, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies...
► Artikel lesen
10.06.Xilio Therapeutics erweitert Vorstand mit neuem Direktor2
10.06.Xilio Therapeutics, Inc.: Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of Directors3
10.06.Xilio Therapeutics, Inc. - 8-K, Current Report3
XILIO THERAPEUTICS Aktie jetzt für 0€ handeln
06.06.Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Closing of $50.0 Million Public Offering2
03.06.Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)94WALTHAM, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies...
► Artikel lesen
02.06.Xilio Therapeutics announces pricing of $50 million public offering2
02.06.Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Pricing of $50.0 Million Public Offering1
02.06.Xilio Therapeutics announces public offering; shares down1
02.06.Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Proposed Public Offering2
02.06.Xilio Therapeutics announces public offering of warrants1
02.06.Xilio Therapeutics, Inc. - 8-K, Current Report2
01.06.Xilio Therapeutics, Inc. (XLO) Reports 26% Response in Colon Cancer Drug Trial4
31.05.Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Updated Phase 2 Data for Vilastobart, a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer7526% preliminary objective response rate observed in heavily pre-treated patients with metastatic microsatellite stable colorectal cancer (MSS CRC) without liver metastases Deep and durable responses...
► Artikel lesen
08.05.Xilio Therapeutics, Inc. - 10-Q, Quarterly Report2
08.05.Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2025 Financial Results211Updated Phase 2 data to be presented at ASCO for vilastobart, a tumor-activated, Fc-enhanced, anti-CTLA-4, in combination with atezolizumab in patients with metastatic microsatellite stable colorectal...
► Artikel lesen
08.05.Xilio Therapeutics, Inc. - 8-K, Current Report3
02.05.Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)144WALTHAM, Mass., May 02, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies...
► Artikel lesen
23.04.Xilio Therapeutics, Inc.: Xilio Therapeutics to Present Updated Phase 2 Data for Vilastobart, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Combination with Atezolizumab in Patients with Microsatellite Stable Colorectal Cancer at the 2025 ...2
Weiter >>
50 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1